ArticleCureus2025
Primary Cutaneous Histiocytic Sarcoma: A Rare Case.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histiocytic sarcoma is a rare malignancy composed of neoplastic cells that resemble macrophages in morphology and immunoprofile. It manifests in lymph nodes or extranodal sites, with the majority occurring in the gastrointestinal tract, central nervous system, spleen, skin, and soft tissues. Clinical manifestations depend on organ involvement, with systemic symptoms, including fever, fatigue, night sweats, weight loss, and weakness. A significant proportion of patients are diagnosed at an advanced stage, which is associated with high mortality rates. In this report, we highlight the case of an 80-year-old who displayed a subcutaneous forearm lesion. Histological evaluation confirmed the diagnosis of cutaneous histiocytic sarcoma, with tumor cells expressing CD163 and CD68. A multidisciplinary team decided on supplementary adjuvant radiotherapy, considering the unifocal presentation and complete surgical excision of the lesion. The patient remains disease-free at one-year follow-up. This case emphasizes that a unifocal and localized manifestation of the malignancy has a more favorable outcome. Although treatment protocols have not yet been standardized, recent advances in genomic profiling may offer opportunities for targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.